Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Demographics and baseline characteristics of patients in the dose-expansion population by cohort.</p>
Gardado en:
Títulos similares
-
Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado: (2025) -
Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado: (2025) -
Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado: (2025) -
Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado: (2025) -
Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
por: Kristoffer Staal Rohrberg (15009138)
Publicado: (2025)